演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

スニチニブにより壊死性遊走性紅斑が軽快したグルカゴノーマ

演題番号 : P110-8

[筆頭演者]
演者)河原 辰由樹:1 
[共同演者]
越智 宣昭:1、山根 弘路:1、山岸 智子:1、長﨑 泰有:1、中川 望:1、中西 秀和:1、瀧川 奈義夫:1

1:川崎医科大学・総合内科

 

A 61-year-old female presented with progressive glucagonoma of a pancreatic neuroendocrine tumor, accompanied by necrolytic migratory erythema. She had previously undergone surgical resection, octreotide treatment, transarterial embolization, and chemotherapy featuring epirubicin, 5-fluorouracil, and dacarbazine, over a period of 8 years. Her necrolytic migratory erythema status correlated with the extent of disease control. However, her glucagonoma and necrolytic migratory erythema did not respond to everolimus; therefore, we started sunitinib (37.5 mg/day) treatment in an effort to inhibit vascular endothelial growth factor- and platelet-derived growth factor-mediated receptor signaling. Four months later, magnetic resonance imaging revealed that the liver metastasis had responded to this treatment, associated with improvement of the necrolytic migratory erythema. The serum glucagon level (initially 803 pg/mL; reference level 71-174 pg/mL) fell to 425 pg/mL. Successful treatment of glucagonoma should improve necrolytic migratory erythema. Here, we report the first case of necrolytic migratory erythema developing secondarily to metastatic glucagonoma, and exhibiting sensitivity to sunitinib.

キーワード

臓器別:NET(神経内分泌腫瘍)

手法別:分子標的治療

前へ戻る